These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1308 related items for PubMed ID: 11960265

  • 21. Primary mediastinal large B-cell lymphoma: results of intensive chemotherapy regimens (MACOP-B/VACOP-B) plus involved field radiotherapy on 53 patients. A single institution experience.
    Mazzarotto R, Boso C, Vianello F, Aversa MS, Chiarion-Sileni V, Trentin L, Zambello R, Muzzio PC, Fiore D, Sotti G.
    Int J Radiat Oncol Biol Phys; 2007 Jul 01; 68(3):823-9. PubMed ID: 17379431
    [Abstract] [Full Text] [Related]

  • 22. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy.
    Federico M, Bellei M, Brice P, Brugiatelli M, Nagler A, Gisselbrecht C, Moretti L, Colombat P, Luminari S, Fabbiano F, Di Renzo N, Goldstone A, Carella AM, EBMT/GISL/ANZLG/SFGM/GELA Intergroup HD01 Trial.
    J Clin Oncol; 2003 Jun 15; 21(12):2320-5. PubMed ID: 12805333
    [Abstract] [Full Text] [Related]

  • 23. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
    Zinzani PL, Stefoni V, Finolezzi E, Brusamolino E, Cabras MG, Chiappella A, Salvi F, Rossi A, Broccoli A, Martelli M.
    Clin Lymphoma Myeloma; 2009 Oct 15; 9(5):381-5. PubMed ID: 19858058
    [Abstract] [Full Text] [Related]

  • 24. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study.
    Lefrère F, Delmer A, Suzan F, Levy V, Belanger C, Djabarri M, Arnulf B, Damaj G, Maillard N, Ribrag V, Janvier M, Sebban C, Casasnovas RO, Bouabdallah R, Dreyfus F, Verkarre V, Delabesse E, Valensi F, McIntyre E, Brousse N, Varet B, Hermine O.
    Leukemia; 2002 Apr 15; 16(4):587-93. PubMed ID: 11960337
    [Abstract] [Full Text] [Related]

  • 25. [High-dose chemotherapy with autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in complete response as consolidation therapy, second report].
    Yamane T, Hirose A, Nakajima Y, Nakane T, Koh H, Takeoka Y, Nakamae M, Yamamura R, Nakamae H, Nakao Y, Mugitani A, Yagi T, Teshima H, Hino M.
    Gan To Kagaku Ryoho; 2006 Feb 15; 33(2):193-8. PubMed ID: 16484855
    [Abstract] [Full Text] [Related]

  • 26. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.
    Stewart DA, Guo D, Glück S, Morris D, Chaudhry A, deMetz C, Klassen J, Brown CB, Russell JA.
    Bone Marrow Transplant; 2000 Aug 15; 26(4):383-8. PubMed ID: 10982284
    [Abstract] [Full Text] [Related]

  • 27. [Trial of front-line intensive chemotherapy followed by peripheral blood stem cell transplantation in high-intermediate and high risk non-Hodgkin's lymphoma patients].
    Motomura S, Hashimoto C, Kodama F, Maruta A, Sakai R, Fujita H, Tomita N, Fujisawa S, Harano H, Koharazawa H, Fujimaki K, Kanamori H, Ishigatsubo Y.
    Rinsho Ketsueki; 2005 May 15; 46(5):350-7. PubMed ID: 16444968
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an "Intergruppo Italiano Linfomi" randomized trial.
    Vitolo U, Liberati AM, Cabras MG, Federico M, Angelucci E, Baldini L, Boccomini C, Brugiatelli M, Calvi R, Ciccone G, Genua A, Deliliers GL, Levis A, Parvis G, Pavone E, Salvi F, Sborgia M, Gallo E, Intergruppo Italiano Linfomi.
    Haematologica; 2005 Jun 15; 90(6):793-801. PubMed ID: 15951292
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma.
    Majhail NS, Weisdorf DJ, Defor TE, Miller JS, McGlave PB, Slungaard A, Arora M, Ramsay NK, Orchard PJ, MacMillan ML, Burns LJ.
    Biol Blood Marrow Transplant; 2006 Oct 15; 12(10):1065-72. PubMed ID: 17084370
    [Abstract] [Full Text] [Related]

  • 36. A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma.
    Coso D, Sebban C, Boulat O, Biron P, Rey J, Aurran T, Chabannon C, Xerri L, Chetaille B, Esterni B, Ivanov V, Stoppa AM, Schiano de Collela JM, Gastaut JA, Maraninchi D, Bouabdallah R.
    Bone Marrow Transplant; 2006 Aug 15; 38(3):217-22. PubMed ID: 16770316
    [Abstract] [Full Text] [Related]

  • 37. Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL.
    Linch DC, Yung L, Smith P, Maclennan K, Jack A, Hancock B, Cunningham D, Hoskin P, Qian W, Holte H, Boesen AM, Grigg A, Browett P, Trneny M.
    Br J Haematol; 2010 Apr 15; 149(2):237-43. PubMed ID: 20201949
    [Abstract] [Full Text] [Related]

  • 38. Is high-dose chemotherapy after primary chemotherapy a therapeutic option for patients with primary mediastinal nonseminomatous germ cell tumor?
    Banna GL, De Giorgi U, Ferrari B, Castagna L, Alloisio M, Marangolo M, Rosti G, Santoro A.
    Biol Blood Marrow Transplant; 2006 Oct 15; 12(10):1085-91. PubMed ID: 17084372
    [Abstract] [Full Text] [Related]

  • 39. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors.
    Caballero MD, Rubio V, Rifon J, Heras I, García-Sanz R, Vázquez L, Vidriales B, del Cañizo MC, Corral M, Gonzalez M, León A, Jean-Paul E, Rocha E, Moraleda JM, San Miguel JF.
    Bone Marrow Transplant; 1997 Sep 15; 20(6):451-8. PubMed ID: 9313877
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 66.